1. Technical Field
The application includes a description of improved processes for the preparation of substituted 4-sulfonyl quinolines which are useful as intermediates in the preparation of agents for the treatment of hepatitis C viral (HCV) infections.
2. Background Information
4-Sulfonyl substituted quinolines which are preparable according to the methods described herein have been found to be useful as intermediates in the preparation of certain anti-HCV agents. Examples of such anti-HCV agents are described, e.g., in U.S. Patent Application Publication Nos. 2005/0020503 A1 and 2005/0080005 A1, both herein incorporated by reference. Further examples of such anti-HCV agents are described in U.S. Patent Application Publication No. US 2005/0267151 A1, also incorporated by reference herein. The '151 publication also describes processes for the synthesis of substituted sulfonyl quinolines intermediates useful for preparing the agents. The substituted sulfonyl quinolines are prepared by amide coupling followed by cyclization in the presence of a strong base, tosylation and sulfonylation under acid conditions. However, there is a continuing need to develop alternative processes which may be more practical and economically useful for the preparation of these substituted sulfonyl quinolines.
Among the problems addressed by the present invention is the provision of a process that allows the use of economical reagents and requires a low number of operation steps for the manufacture of these compounds.
The substituted sulfonyl quinolines of the present invention are prepared from substituted aromatic amino-ketones via amide formation with an acid followed by cyclization in the presence of an alkali or alkaline earth metal base and further conversion to a sulfone via a sulfonate intermediate. The present invention has the advantage of utilizing low cost, a lower number of steps and readily available starting materials and reagents. In addition, this procedure avoids the need for isolation of some intermediates, and minimizes the number of reagents operations for an overall faster cycle time.
One embodiment of the process of the present invention can be briefly summarized by the following scheme:
in which each Alk is independently C1-C6 alkyl; X is a halogen atom; R is C1-C10 alkyl, aryl, particularly C6, or heteroaryl; R1 is alkyl, particularly C1-C10 alkyl, more particularly C1-C6 alkyl, more particularly C1-C3 alkyl, or such alkyl which is optionally interrupted by one or more heteroatoms, e.g., —O—, —NH—, —C(═O)—, —N—(C1-C10 alkyl)-, —S—, or R1 is (C3-7)cycloalkyl and (C3-7)cycloalkyl(C1-4)alkyl-, wherein said cycloalkyl or cycloalkylalkyl may be mono-, di- or tri-substituted with (C1-3)alkyl; M1 is an alkali or alkali earth metal such as Na+, K+, Cs+, Mg2+ or Ca2+; R2 is C1-C10 alkyl, aryl, particularly C6, or heteroaryl, and Het is a heterocyclic radical as defined below. Each of the alkyl, aryl, heteroaryl and Het groups may optionally be substituted by alkyl, cycloalkyl, alkoxy, cycloalkoxy, phenylalkyl, alkenyl, amino, substituted amino, or amido (i.e., —NH—CO—R or —CO—NH—R).
Examples of the intermediate compounds of formula I which can be prepared according to the invention are described in U.S. Patent Application Publication No. 2005/0267151 A1, all incorporated by reference herein. Further examples of such compounds are as follows:
Terms not specifically defined herein should be given the meanings that would be given to them by one of skill in the art in light of the disclosure and the context. As used in the specification, however, unless specified to the contrary, the following terms have the meaning indicated and the following conventions are adhered to.
In the groups, radicals, or moieties defined above and below, the number of carbon atoms is often specified preceding the group, for example, (C1-10)alkyl means an alkyl group or radical having 1 to 10 carbon atoms and (C3-7)cycloalkyl means a cycloalkyl group having from 3 to 7 carbon atoms in the ring. In general, for groups comprising two or more subgroups, the last named group is the point of attachment for the radical. For example, “cycloalkylalkyl” means a monovalent radical of the formula cycloalkyl-alkyl- and phenylalkyl means a monovalent radical of the formula phenyl-alkyl-. Unless otherwise specified below, conventional definitions of terms control and conventional stable atom valences are presumed and achieved in all formulas and groups.
The term “alkyl” as used herein, either alone or in combination with another substituent, means acyclic, straight or branched chain alkyl substituents containing the specified number of carbon atoms.
The term “alkoxy” as used herein, either alone or in combination with another substituent, means an alkyl group as defined above linked as a substituent through an oxygen atom: alkyl-O—.
The term “aryl” such as “C6 or C10 aryl” as used herein, either alone or in combination with another substituent, means either an aromatic cyclic system containing the stated number of carbon atoms, for example, an aromatic monocyclic system containing 6 carbon atoms or an aromatic bicyclic system containing 10 carbon atoms. For example, aryl includes a phenyl or a naphthyl ring system.
The term “Het” as used herein, either alone or in combination with another substituent, means a monovalent substituent derived by removal of a hydrogen from a five-, six-, or seven-membered saturated or unsaturated (including aromatic) heterocycle containing carbon atoms and from one to four ring heteroatoms selected from nitrogen, oxygen and sulfur. Examples of suitable heterocycles for providing the Het groups include: tetrahydrofuran, thiophene, diazepine, isoxazole, piperidine, dioxane, morpholine, pyrimidine or
The term “Het” also includes those from a heterocycle as defined above fused to one or more other cyclic moiety, i.e., either a heterocycle or a carbocycle, each of which may be saturated or unsaturated. One such example includes thiazolo[4,5-b]-pyridine. Although generally included within the term “Het”, the term “heteroaryl” as used herein precisely defines an unsaturated heterocycle for which the double bonds form an aromatic system. Suitable examples of heteroaromatic systems include: quinoline, indole, pyridine,
In general, all tautomeric forms and isomeric forms and mixtures, whether individual geometric isomers or optical isomers or racemic or non-racemic mixtures of isomers, of a chemical structure or compound are intended, unless the specific stereochemistry or isomeric form is specifically indicated in the compound name or structure.
The following chemicals may be referred to by these abbreviations:
In the synthetic schemes below, unless specified otherwise, all the substituent groups in the chemical formulas shall have the same meanings as described herein unless otherwise specified. The reactants used in the synthetic schemes described below may be obtained either as described herein, or if not described herein, are themselves either commercially available or may be prepared from commercially available materials by methods known in the art. Certain starting materials, for example, may be obtained by methods described in U.S. Patent Application Publication No. US 2005/0267151 A1.
Optimum reaction conditions and reaction times may vary depending on the particular reactants used. Unless otherwise specified, solvents, temperatures, pressures, and other reaction conditions may be readily selected by one of ordinary skill in the art. Specific procedures are provided in the Synthetic Examples section. Typically, reaction progress may be monitored by thin layer chromatography or High Pressure Liquid Chromatography (HPLC), if desired, and intermediates and products may be purified by chromatography on silica gel and/or by recrystallization, and characterized by one or more of the following techniques: NMR, mass spectroscopy and melting point.
In one embodiment, the present invention is directed to the following general multi-step synthetic method for preparing the compounds of formula I as set forth in Scheme I below. In other embodiments, the invention is directed to each of the individual steps of Scheme I and any combination of two or more successive steps of Scheme I. The invention may also be directed to the intermediate compounds set forth in Scheme I.
in which each Alk is independently C1-C6 alkyl; X and X1 are independently halogen atoms; R is C1-C10 alkyl, C6 aryl or heteroaryl; R1 is alkyl, particularly C1-C10 alkyl, more particularly C1-C6 alkyl, more particularly C1-C3 alkyl, or such alkyl which is optionally interrupted by one or more heteroatoms, e.g., —O—, —NH—, —C(═O)—, —N—(C1-C10 alkyl)-, —S—, or R1 is (C3-7)cycloalkyl and (C3-7)cycloalkyl(C1-4)alkyl-, wherein said cycloalkyl or cycloalkylalkyl may be mono-, di- or tri-substituted with (C1-3)alkyl; M1 and M2 are, independently, an alkali or alkali earth metal such as Na+, K+, Cs+, Mg2+ or Ca2+; R2 is C1-C10 alkyl, C6 aryl or heteroaryl, and Het is a heterocyclic radical as defined above.
In the first step, compound II is acylated with compound III to obtain compound IV. For the conversion of II to IV, acylation is achieved by either first converting carboxylic acid III to an activated form such as an acid chloride or by using standard peptide coupling protocols. The preferred method is to create the acid chloride of compound III using oxalyl chloride or thionyl chloride. This activated species is then coupled with the aniline compound II in any organic solvent or in water, with or without an added base. The preferred solvents are MeCN, NMP and THF and the preferred base (if used) is triethylamine. The reaction temperature is preferably from −30° C. to 150° C., more preferably from −20° C. to 50° C. Compound IV can be isolated, or alternatively be used for next step directly without isolation.
In the next steps, compound IV is cyclized in the presence of an alkali metal or alkaline earth metal base to obtain compound V as an alkali metal or alkaline earth metal salt. Compound V can be isolated and purified as its neutral form (hydroxyquinoline) by neutralization and filtration. But, preferably, it is subjected to sulfonylation conditions directly without isolation in a one-pot process to furnish sulfonate VI. The sulfonate VI is in turn converted to final compound I by reaction with a sulfonate salt. Preferably, the conversion from IV to I is also performed directly without isolation so that the three steps of proceeding from compound IV to compound I are performed all in a one-pot process.
For the conversion of IV to V in Scheme I, any alkali metal or alkaline earth metal base capable of forming the enolate can be used, for example, an alkali metal or alkaline earth metal hydroxide, such as KOH, NaOH, CaOH2, and the like, with KOH being preferred. Any solvent which does not react with the enolate can be used, such as water, t-BuOH, THF, dioxane, DMSO, NMP, DME, mixtures thereof and the like, with water or a mixture of THF-water being preferred. The cyclization is preferably performed at a temperature of from 25° C. to 150° C., with 50° C. to 100° C. being particularly preferred.
For the conversion of V to VI in Scheme I, many sulfonylation reagents could be used, such as methanesulfonyl chloride, benzenesulfonyl chloride (PhSO2Cl), toluenesulfonyl chloride (TsCl) and the like, with PhSO2Cl and p-TsCl being preferred. The sulfonylation reaction may be carried out in the same (e.g., if included in a one-pot process) or a different solvent as used in previous step. Any solvent which does not react with the sulfonylation reagent may be used, such as water, DME, diglyme, THF, halocarbons, mixtures thereof, and the like, with THF-water or Me-THF-water mixture being preferred. The reaction temperature is preferably from −20° C. to 150° C. with 0-25° C. being particularly preferred.
For the conversion of VI to I in Scheme I, any sulfonate salt RSO2M2 can be used, where R is as defined previously and M2 is an alkali or alkali earth metal, with PhSO2Na, MeSO2Na and p-MeC6H4SO2Na being preferred. The reaction can be catalyzed by an acid such as HCl, MeSO3H, H2SO4, p-TsOH, H3PO4, HOAc, HO2H, CF3CO2H etc., with HCl being preferred. The sulfone formation step can be run in the same solvent (e.g., if included in a one-pot process) or a different solvent as used in previous step. Any solvent which does not react with the sulfonate VI may be used, such as water, DME, diglyme, THF, halocarbons and the like, with THF-water or a Me-THF-water mixture being preferred. The reaction temperature is preferably from −20° C. to 150° C. with 25-100° C. being particularly preferred.
In another embodiment, the invention is directed to a synthetic method which comprises the above-described step of cyclizing compound IV in the presence of an alkali metal hydroxide or alkaline earth metal hydroxide base to obtain compound V as an alkali metal or alkaline earth metal salt and, in a one-pot process without isolation or neutralization of compound V, subjecting compound V to sulfonylation directly to produce the sulfonate VI. Additionally, the invention is directed to a synthetic method comprising this step coupled with one or more of the other steps described above for Scheme I. For example, one embodiment of the invention is directed to the synthetic method of this step further comprising, in the same one-pot process without isolation of the sulfonate VI, converting to final compound I directly.
Preferred Alk, R, R1, R2, X, X1, Het, M1 and M2 groups in the compounds of formulas II, III, IV, V, VI and I, include:
(A) Preferred definitions of Alk:
and
In another embodiment, the present invention is directed to the intermediate compounds of formula V:
wherein Alk, X, M1, Het and R1 are as defined above. In a preferred embodiment of the compounds of formula V: X is halo, particularly bromine, Alk is methyl and Het-R1 is thiazole substituted by a —NH—C(O)—C1-C6 alkyl or —NH—C1-C6 alkyl group.
Applicants have discovered that the cyclization to obtain the quinoline compound V using an alkali metal or alkaline earth metal base is advantageous since the use of a strong base, such as t-BuOK, KDMO or lithium diisopropylamide, can be avoided. Thus, the later step of quenching the base with an acid is made easier. Further, provision of the alkali metal or alkaline earth metal salt compound V facilitates the sulfonylation reaction, without isolation. This salt reacts better than the neutralized hydroxyquinoline and it is not necessary to add additional base to conduct the reaction. Thus, there is a lower material requirement, less steps and a more environmentally benign result is achieved. In a further embodiment, a further advantage is obtained in that the method allows for a solvent comprising water in the cyclization step to compound V and the other steps conducted in one-pot with that step.
Specific embodiments of the invention are further described by the following non-limiting synthetic examples and description of specific embodiments.
The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.
A. A method comprising reacting a compound of formula IV with an alkali metal or alkaline earth metal base in the presence of a solvent to obtain an alkali metal or alkaline earth metal salt compound of formula V:
B. A method comprising:
wherein Alk, X, M1, R1 and Het are as defined for method A. above and R2 is C1-C10 alkyl, aryl, preferably C6, or heteroaryl; wherein each of the alkyl, aryl, heteroaryl and Het groups above are optionally independently substituted by alkyl, cycloalkyl, alkoxy, cycloalkoxy, phenylalkyl, alkenyl, amino, substituted amino, or amido (i.e., —NH—CO—R or —CO—NH—R, wherein R is C1-C10 alkyl).
C. The method B. described above further comprising reacting compound VI with a sulfonate salt RSO2M2 to obtain a compound of the formula I:
wherein Alk, X, M1, R1, R2 and Het are as defined above; R is C1-C10 alkyl, aryl, preferably C6, or heteroaryl; and M2 is an alkali or alkali earth metal; wherein each of the alkyl, aryl, heteroaryl and Het groups above are optionally independently substituted by alkyl, cycloalkyl, alkoxy, cycloalkoxy, phenylalkyl, alkenyl, amino, substituted amino, or amido (i.e., —NH—CO—R or —CO—NH—R, wherein R is C1-C10 alkyl).
D. The above method C. wherein the compound VI is not isolated before reacting with the sulfonate salt.
E. Any of the above methods A., B., C. or D., which further comprises obtaining compound IV by acylating compound II with compound III in the presence of a solvent, and optionally with addition of a base, to obtain compound IV, the acylation being achieved by either first converting compound III to an acid chloride activated form or by using peptide coupling methods:
wherein Alk, X, R1 and Het are as defined above, each Alk being independently selected.
F. Any of the above methods A., B., C., D. or E., wherein the alkali metal or alkaline earth metal base is an alkali metal or alkaline earth metal hydroxide.
G. Any of the above methods A., B., C., D. or E., wherein the alkali metal or alkaline earth metal base is a potassium hydroxide.
H. Any of the above methods E., F. or G., wherein compound II is converted to an acid chloride by reaction with oxalyl chloride or thionyl chloride.
I. Any of the above methods E., F., G. or H., where the solvent for the acylation of compound II with compound III comprises MeCN, NMP or THF and the optional base is triethylamine and the reaction is conducted at a temperature of from −30° C. to 150° C.
J. Any of the above methods A., B., C., D., E., F., G., H. or I., wherein the solvent for the cyclization of compound IV comprises: water, t-BuOH, THF's, dioxane, DMSO, NMP, or DME and the cyclization reaction is performed at a temperature of from 25° C. to 150° C.
K. Any of the above methods A., B., C., D., E., F., G., H., or I., wherein the solvent for the cyclization of compound IV comprises water.
L. Any of the above methods B., C., D., E., F., G., H., I., J. or K., wherein the sulfonylation reagent for the conversion of compound V to compound VI is methanesulfonyl chloride, benzenesulfonyl chloride or toluenesulfonyl chloride and the reaction temperature for the conversion is from −20° C. to 150° C.
M. Any of the above methods C., D., E., F., G., H., I., J., K. or L., wherein the sulfonate salt RSO2M2 for the conversion of compound VI to compound I is PhSO2Na, MeSO2Na or p-MeC6H4SO2Na.
N. Any of the above methods C., D., E., F., G., H., I., J., K., L. or M., wherein the conversion of compound VI to compound I is catalyzed by an acid selected from HCl, MeSO3H, H2SO4, p-TsOH, H3PO4, HOAc, HO2H, and CF3CO2H.
O. Any of the above methods C., D., E., F., G., H., I., J., K., L. or M., wherein the conversion of compound VI to compound I is catalyzed by HCl.
P. Any of the above methods C., D., E., F., G., H., I., J., K., L., M., N. or O., wherein the conversion of compound VI to compound I is at a reaction temperature of from −20° C. to 150° C.
Q. Any of the above methods A., B., C., D., E., F., G., H., I., J., K., L., M., N., O., or P., wherein, in the compounds:
R. An intermediate compound of formula V:
wherein Alk is a C1-C6 alkyl group; X is a halogen atom; M1 is an alkali metal or alkali earth metal; R1 is alkyl, particularly C1-C10 alkyl, more particularly C1-C6 alkyl, more particularly C1-C3 alkyl, or such alkyl which is optionally interrupted by one or more heteroatoms, e.g., —O—, —NH—, —C(═O)—, —N—(C1-C10 alkyl)- or —S—, or R1 is (C3-7)cycloalkyl and (C3-7)cycloalkyl(C1-4)alkyl-, wherein said cycloalkyl or cycloalkylalkyl may be mono-, di- or tri-substituted with (C1-3)alkyl; and Het is a monovalent substituent derived by removal of a hydrogen from a five-, six-, or seven-membered saturated or unsaturated (including aromatic) heterocycle containing carbon atoms and from one to four ring heteroatoms selected from nitrogen, oxygen and sulfur; wherein each of the alkyl, aryl, heteroaryl and Het groups above are optionally independently substituted by alkyl, cycloalkyl, alkoxy, cycloalkoxy, phenylalkyl, alkenyl, amino, substituted amino, or amido (i.e., —NH—CO—R or —CO—NH—R).
S. An intermediate compound of embodiment R where: X is bromine, Alk is methyl and Het-R1 is thiazole substituted by a —NH—C(O)—C1-C6 alkyl or —NH—C1-C6 alkyl group.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/US2010/027747 | 3/18/2010 | WO | 00 | 1/5/2012 |
Number | Date | Country | |
---|---|---|---|
61161452 | Mar 2009 | US |